Table 4

Odds ratios for non-steroidal anti-inflammatory drug (NSAID) use stratified on the manganese superoxide dismutase (MnSOD) genotype (multiplicative scale) and joint effects (additive scale) (phase 2 invasive and CIS studies only)

Val/Val or Val/Ala MnSOD genotype

Ala/Ala MnSOD genotype

Use of NSAIDs

Cases/controls

Odds ratio (95% CI) ^a

Cases/controls

Odds ratio (95% CI) ^a

ICR (95% CI)

Multiplicative scale

Never

105/48

Referent

19/16

Referent

Occasional

511/420

0.6 (0.4–0.8)

142/127

0.8 (0.4–1.9)

Short term

148/141

0.4 (0.3–0.7)

43/36

0.9 (0.4–2.4)

Long term

218/200

0.4 (0.3–0.7)

58/58

0.9 (0.4–2.1)

Additive scale

Never

105/48

Referent

19/16

0.5 (0.2–1.3)

Occasional

511/420

0.5 (0.4–0.8)

142/127

0.5 (0.3–0.7)

0.4 (-0.1, 0.9)

Short term

148/141

0.4 (0.3–0.7)

43/36

0.5 (0.3–1.0)

0.5 (-0.1, 1.1)

Long term

218/200

0.4 (0.3–0.7)

58/58

0.4 (0.2–0.7)

0.4 (-0.1, 0.9)

CI, confidence interval; ICR, interaction contrast ratio. ^a Adjusted for offsets, age, race, family history, age at menarche, age at first full-term pregnancy/parity composite, smoking duration, alcohol use, lactation, menopausal status, oral contraceptive use, education, body mass index, and waist–hip ratio.

Millikan et al. Breast Cancer Res 2004 6:R264   doi:10.1186/bcr786